Business
Spectral's EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
TORONTO, April 9 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) today announced that its Endotoxin ...
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n\nTORONTO, April 9 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) today\nannounced that its Endotoxin Activity Assay (EAA(TM)), an FDA cleared\ndiagnostic for risk of sepsis, will be used to measure endotoxin levels during\nthe enrolment of patients in a Phase III sub study, part of a multinational\nclinical trial evaluating the safety and effectiveness of a treatment for\nsevere sepsis.\n\n\n"Spectral is pleased that a major international pharmaceutical company is\nusing the EAA(TM) in a proportion of patients in its study," said Dr. Paul\nWalker, President and CEO of Spectral Diagnostics. "We are optimistic that the\ndata from this sub study will promote subsequent use of the EAA(TM) to\nidentify patients most likely to benefit from specific anti-endotoxin\ntherapy."\n\n\nCurrently, in North America, there is no available drug to directly\ncounter the effects of endotoxin. The Phase III sub study will explore the\nutility of partnering a reliable measurement of endotoxin, the EAA(TM), with a\ntargeted anti-endotoxin treatment aimed at reducing mortality rates for\npatients with severe sepsis. Spectral's unique assay helps identify endotoxin\nlevels in patients and enables appropriate and rapid application of\ntherapeutics.\n\n\nSpectral has a contractual agreement to supply EAA(TM) equipment, test\nkits and technical expertise for use in the study that is expected to run\nuntil mid 2010.\n\n\nAbout Spectral Diagnostics\n\n\nSpectral is a developer of innovative technologies for comprehensive\ndisease management. Spectral's lead product is its EAA(TM) Endotoxin Activity\nAssay, the only FDA approved diagnostic for the measurement of endotoxin.\nSpectral technologies provide accurate and timely information to clinicians\nenabling the early initiation of appropriate and targeted therapy. Spectral is\nlisted on TSX under the symbol SDI.\n\n\nForward-looking statement\n\n\nInformation in this news release that is not current or historical\nfactual information may constitute forward-looking information within the\nmeaning of securities laws. Implicit in this information, particularly in\nrespect of the future outlook of Spectral and anticipated events or results,\nare assumptions based on beliefs of Spectral's senior management as well as\ninformation currently available to it. While these assumptions were co...